Uceris (Ulcerative Colitis) - Forecast and Market Analysis to 2022: Key Players Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio

ResearchMoz added Latest Research Report titled " Uceris (Ulcerative Colitis) - Forecast and Market Analysis to 2022 " to it's Large Report database.

During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.

Uceris is a synthetic steroid of the glucocorticosteroid family that is indicated for mild-to-moderate UC. It is formulated as a slow-release foam that is administered rectally. Uceris binds to glucocorticoid receptors and causes suppression of endogenous cortisol concentrations and impairment of the hypothalamus-pituitary-adrenal (HPA) axis function. Budesonide has mainly anti-inflammatory activity, and due to an extended first-pass effect, Uceris has less systemic absorption than other corticosteroids.

Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=195946

Scope

• Overview of Ulcerative Colitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Uceris including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Uceris for the top seven countries from 2012 to 2022.
• Sales information covered for the US, France, Germany, Italy, Spain, the UK and Canada.

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for Ulcerative Colitis
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of Uceris performance
• Obtain sales forecast for Uceris from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Canada)

Read All Healthcare Market Research Reports @ http://www.researchmoz.us/healthcare-market-reports-56.html

Table of Contents

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7

2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 10

3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 13
3.2 Symptoms 15
3.2.1 Quality of Life 15

4 Disease Management 17
4.1 Diagnosis and Treatment Overview 17
4.1.1 Diagnosis 17
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 20
4.1.3 Clinical Practice 22

5 Competitive Assessment 26
5.1 Overview 26
5.2 Strategic Competitor Assessment 27

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket
Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG